Ilia I. Ouspenski

Array ( [id] => 6228883 [patent_doc_number] => 20100183621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-07-22 [patent_title] => 'Fully human antibodies against human 4-1BB' [patent_app_type] => utility [patent_app_number] => 12/653137 [patent_app_country] => US [patent_app_date] => 2009-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 34 [patent_no_of_words] => 11909 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0183/20100183621.pdf [firstpage_image] =>[orig_patent_app_number] => 12653137 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8283048 [patent_doc_number] => 08217149 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-07-10 [patent_title] => 'Anti-PD-L1 antibodies, compositions and articles of manufacture' [patent_app_type] => utility [patent_app_number] => 12/633339 [patent_app_country] => US [patent_app_date] => 2009-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 21 [patent_no_of_words] => 66000 [patent_no_of_claims] => 61 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12633339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7774229 [patent_doc_number] => 08119604 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-02-21 [patent_title] => 'Polypeptide formulation' [patent_app_type] => utility [patent_app_number] => 12/632690 [patent_app_country] => US [patent_app_date] => 2009-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 7790 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/119/08119604.pdf [firstpage_image] =>[orig_patent_app_number] => 12632690 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8796646 [patent_doc_number] => 08435514 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-05-07 [patent_title] => 'Method for the treatment of neurodegenerative diseases' [patent_app_type] => utility [patent_app_number] => 13/132670 [patent_app_country] => US [patent_app_date] => 2009-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 28 [patent_no_of_words] => 7178 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13132670 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7579744 [patent_doc_number] => 20110293627 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-01 [patent_title] => 'COMBINATION THERAPY TO ENHANCE NK CELL MEDIATED CYTOTOXICITY' [patent_app_type] => utility [patent_app_number] => 13/132346 [patent_app_country] => US [patent_app_date] => 2009-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 4436 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0293/20110293627.pdf [firstpage_image] =>[orig_patent_app_number] => 13132346 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9355097 [patent_doc_number] => 08673630 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2014-03-18 [patent_title] => 'βGI-IgG intron for enhanced anti-IGF1R expression' [patent_app_type] => utility [patent_app_number] => 13/128774 [patent_app_country] => US [patent_app_date] => 2009-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 20318 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13128774 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6234907 [patent_doc_number] => 20100266611 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-10-21 [patent_title] => 'Enhancement of Immune Responses By 4-1BB-Binding Agents' [patent_app_type] => utility [patent_app_number] => 12/614150 [patent_app_country] => US [patent_app_date] => 2009-11-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 21581 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0266/20100266611.pdf [firstpage_image] =>[orig_patent_app_number] => 12614150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8197076 [patent_doc_number] => 20120121604 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-05-17 [patent_title] => 'COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES' [patent_app_type] => utility [patent_app_number] => 13/384900 [patent_app_country] => US [patent_app_date] => 2009-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 20607 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0121/20120121604.pdf [firstpage_image] =>[orig_patent_app_number] => 13384900 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8201553 [patent_doc_number] => 08188238 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2012-05-29 [patent_title] => 'Recombinantly produced antibody' [patent_app_type] => utility [patent_app_number] => 12/608390 [patent_app_country] => US [patent_app_date] => 2009-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 43 [patent_no_of_words] => 24449 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/188/08188238.pdf [firstpage_image] =>[orig_patent_app_number] => 12608390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6467557 [patent_doc_number] => 20100040633 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-02-18 [patent_title] => 'BINDING COMPOSITIONS: RELATED REAGENTS' [patent_app_type] => utility [patent_app_number] => 12/579447 [patent_app_country] => US [patent_app_date] => 2009-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 11564 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0040/20100040633.pdf [firstpage_image] =>[orig_patent_app_number] => 12579447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9153480 [patent_doc_number] => 08586386 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2013-11-19 [patent_title] => 'Peptide or protein comprising a C′-D loop of the CD28 receptor family' [patent_app_type] => utility [patent_app_number] => 12/578558 [patent_app_country] => US [patent_app_date] => 2009-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 12 [patent_no_of_words] => 5933 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12578558 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6625522 [patent_doc_number] => 20100034828 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-02-11 [patent_title] => 'Method of Increasing Radiation Sensitivity by Inhibition of Beta One Integrin' [patent_app_type] => utility [patent_app_number] => 12/575411 [patent_app_country] => US [patent_app_date] => 2009-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 11821 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0034/20100034828.pdf [firstpage_image] =>[orig_patent_app_number] => 12575411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6110312 [patent_doc_number] => 20110189189 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-08-04 [patent_title] => 'COMBINATION OF CD137 ANTIBODY AND CTLA-4 ANTIBODY FOR THE TREATMENT OF PROLIFERATIVE DISEASES' [patent_app_type] => utility [patent_app_number] => 13/122630 [patent_app_country] => US [patent_app_date] => 2009-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 11942 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0189/20110189189.pdf [firstpage_image] =>[orig_patent_app_number] => 13122630 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6618588 [patent_doc_number] => 20100099850 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-22 [patent_title] => 'HUMAN CYTOKINE RECEPTOR' [patent_app_type] => utility [patent_app_number] => 12/573046 [patent_app_country] => US [patent_app_date] => 2009-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61387 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0099/20100099850.pdf [firstpage_image] =>[orig_patent_app_number] => 12573046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7575702 [patent_doc_number] => 20110271358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-03 [patent_title] => 'HUMAN ANTI-PD-1, PD-L1, AND PD-L2 ANTIBODIES AND USES THEREFOR' [patent_app_type] => utility [patent_app_number] => 13/120406 [patent_app_country] => US [patent_app_date] => 2009-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 41604 [patent_no_of_claims] => 57 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0271/20110271358.pdf [firstpage_image] =>[orig_patent_app_number] => 13120406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 4639088 [patent_doc_number] => 08017114 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2011-09-13 [patent_title] => 'Human CTLA-4 antibodies and their uses' [patent_app_type] => utility [patent_app_number] => 12/564756 [patent_app_country] => US [patent_app_date] => 2009-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 27 [patent_no_of_words] => 40143 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/08/017/08017114.pdf [firstpage_image] =>[orig_patent_app_number] => 12564756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6601280 [patent_doc_number] => 20100098710 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-22 [patent_title] => 'Anti-IGF-1R Antibodies and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 12/559415 [patent_app_country] => US [patent_app_date] => 2009-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 89658 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0098/20100098710.pdf [firstpage_image] =>[orig_patent_app_number] => 12559415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6608010 [patent_doc_number] => 20100099147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-04-22 [patent_title] => 'Anti-IGF-1R Antibodies and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 12/559411 [patent_app_country] => US [patent_app_date] => 2009-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 89664 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0099/20100099147.pdf [firstpage_image] =>[orig_patent_app_number] => 12559411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6352373 [patent_doc_number] => 20100022028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-01-28 [patent_title] => 'HUMAN OX2 RECEPTORS' [patent_app_type] => utility [patent_app_number] => 12/558286 [patent_app_country] => US [patent_app_date] => 2009-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 13590 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0022/20100022028.pdf [firstpage_image] =>[orig_patent_app_number] => 12558286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6544579 [patent_doc_number] => 20100125130 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2010-05-20 [patent_title] => 'TUMOUR NECROSIS FACTOR BINDING LIGANDS' [patent_app_type] => utility [patent_app_number] => 12/557309 [patent_app_country] => US [patent_app_date] => 2009-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 13409 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0125/20100125130.pdf [firstpage_image] =>[orig_patent_app_number] => 12557309 [rel_patent_id] =>[rel_patent_doc_number] =>)